AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00048737
Drug: Zevalin Radioimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
Trial: NCT00048737
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals
Trial: NCT01000064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules taken every morning for 6 weeks.
Trial: NCT02354170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03777956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo are given as capsules and taken orally twice a day.
Trial: NCT00606697
Drug: GR205171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 milligrams (mg)
Trial: NCT00606697
Drug: GW597599
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg
Trial: NCT00176566
Drug: Lozenge Intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
Trial: NCT01518192
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg bid; 15 days
Trial: NCT00085540
Drug: depsipeptide
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00798967
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
Trial: NCT02474017
Drug: MGR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
Trial: NCT02444897
Drug: IV PCA Fentanyl+nefopam+Ramosetron
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
Trial: NCT00001262
Drug: Copper Histidine
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04013581
Drug: TZD group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg
Trial: NCT04013581
Drug: SGLT-2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg
Trial: NCT02180737
Drug: Dexmeditomedine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00096746
Drug: LPV/RTV + 2NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Variable, Twice daily, 48 weeks.
Trial: NCT00817986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT03047993
Drug: Glutaminase Inhibitor CB-839
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00517556
Drug: CCOCP
RxNorm normalized name: Calcium Carbonate and Cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
Trial: NCT00774735
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg given in combination with lopinavir/ritonavir
Trial: NCT00774735
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg in combination with darunavir/ritonavir
Trial: NCT02505087
Drug: N-Acetylcysteine followed by Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.~Treatment periods are separated by a 2 month washout.
Trial: NCT04207112
Drug: Standard Drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
Trial: NCT02505087
Drug: Placebo followed by N-Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
Trial: NCT00700297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet placebo per day for 4 months
Trial: NCT01253512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT00108849
Drug: estradiol, 10 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04592380
Drug: Stage 1: Placebo (double-blinded)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
Trial: NCT04592380
Drug: Stage 2: Standard of Care (open-label)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
Trial: NCT02041715
Drug: TKM-100802 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT02041715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT03959540
Drug: Levodopa (L-DOPA) + Standard care
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
Trial: NCT00003207
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01697527
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04242927
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routinely apply urea ointment and provide best supportive care.
Trial: NCT00954369
Drug: [F-18]W372
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The individual doses of \[F-18\]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging.
Trial: NCT00446316
Drug: Antacids (Mg-Al-based)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
Trial: NCT03119038
Drug: Bupivicaine + epinephrine
RxNorm normalized name: bupivacaine / epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
Trial: NCT03119038
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative periarticular injection of 30 mg
Trial: NCT03206944
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
Trial: NCT02782455
Drug: CDobi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesylate is administered
Trial: NCT04429347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Friday night: 1 capsule, Saturday night: 2 capsule, Sunday night: choice of 1 or 2 capsules
Trial: NCT01158534
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02887534
Drug: Placebo1401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00820703
Drug: Nexagon®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00820703
Drug: Nexagon® vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02306772
Drug: TP05 Coating A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One radio-labelled tablet given to subjects
Trial: NCT02099916
Drug: Gonadotropins
RxNorm normalized name: GONADOTROPINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
Trial: NCT04116632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT00869336
Drug: Placebo Comparator -2 wks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied daily for 2 weeks
Trial: NCT00869336
Drug: Placebo Comparator - 4 wks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied daily for 4 weeks
Trial: NCT01885195
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
Trial: NCT02941107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
Trial: NCT02647762
Drug: CF101 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 tablets, 1mg BID for 12 weeks
Trial: NCT02647762
Drug: CF101 2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 tablets, 2 mg BID for 12 weeks
Trial: NCT03783429
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be given orally
Trial: NCT02284906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone placebo-matching tablets
Trial: NCT01180374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (about a quarter spoon of alcohol with no CBD).
Trial: NCT01180374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
Trial: NCT01703819
Drug: Neurexan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
Trial: NCT00070200
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00070200
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02583789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
Trial: NCT00860340
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
Trial: NCT01975272
Drug: Placebo for ferinject
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00282165
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four weeks double blind placebo treatment
Trial: NCT01149278
Drug: maintain mean arterial pressure between 80-85 mm Hg
RxNorm normalized name: SUS SCROFA ARTERY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
Trial: NCT01892254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (to metformin)
Trial: NCT00115830
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00446316
Drug: Imatimib Mesylate (Gleevec®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
Trial: NCT03511261
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4 placebo capsules for oral intake two times per day
Trial: NCT01938820
Drug: Thymosin-α
RxNorm normalized name: chymosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiviral and antifibrosis therapy
Trial: NCT04585230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roll- On stick with no CBD and no Mineral Oil
Trial: NCT02869217
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01095250
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01095250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01323673
Drug: Vehicle / Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 times a day, 14 total days of study treatment
Trial: NCT00783705
Drug: inositol
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02429596
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch from brand to generic
Trial: NCT00758927
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
Trial: NCT02775864
Drug: Antipsychotic
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New initiation of any antipsychotic medication
Trial: NCT02775864
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New initiation of any antidepressant medications
Trial: NCT02775864
Drug: Mood stabilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New initiation of lithium or any mood stabilizing anti-epileptic drug
Trial: NCT03907488
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00934193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
Trial: NCT06736353
Drug: Beta Blocker Therapy or No Therapy (Control)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blocker therapy or no Beta blocker therapy initiated after type 2 myocardial infarction
Trial: NCT06736353
Drug: RAAS blocker Therapy or No therapy (Control)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAAS blocker therapy or no RAAS blocker therapy initiated after type 2 myocardial infarction
Trial: NCT06736353
Drug: Statin Therapy or No Therapy (Control)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy or no Statin therapy initiated after type 2 myocardial infarction
Trial: NCT06736353
Drug: Single Antiplatelet Therapy or No Therapy (Control)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Antiplatelet Therapy or no antiplatelet therapy initiated after type 2 myocardial infarction
Trial: NCT02826044
Drug: SP2086
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
Trial: NCT00763204
Drug: AN2728 Cream, 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00763204
Drug: AN2728 Cream, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00763204
Drug: AN2728 Cream, 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00763204
Drug: Betnesol®-V Creme, 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03238235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suspension manufactured to mimic Givinostat
Trial: NCT01280123
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
Trial: NCT02151409
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
Trial: NCT03844633
Drug: Depo-Provera Injectable Product
RxNorm normalized name: Depo-Provera Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth
Trial: NCT03844633
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos -- Shot administered within 48 hours of childbirth
Trial: NCT03743064
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered as matching placebo tablets in the fasted condition)
Trial: NCT01011920
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
Trial: NCT02790515
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV infusion prior to transplant on Day -9.
Trial: NCT01530607
Drug: Standard cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
Trial: NCT01741194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken once daily, by mouth
Trial: NCT00156546
Drug: antibiotic to reduce the recurrence of infection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02811484
Drug: Insulin Titration
RxNorm normalized name: INSULIN TITRATION ORAL INHL KIT 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c\>8%
Trial: NCT00715624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Trial: NCT01830153
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01044277
Drug: Gluthathione peroxidases
RxNorm normalized name: peroxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg, two times daily
Trial: NCT04617613
Drug: Omeprazole, Amoxicillin, Metronidazole and Clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
Trial: NCT04617613
Drug: Omeprazole, Amoxicillin and Clarithromycin
RxNorm normalized name: omeprazole, amoxicillin and clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.